1. PPS is languishing in the lows $50's in the wake of the short attack earlier this year.
2. PE for current year is 34, for next year 22.
3. Annual earnings growth has been recently updated to 48%/yr for the next 5 years. So the PPS is currently not reflecting the growth prospects of LGND.
5. What could be a better investment for LGND than something that will return 48%/yr?
Time to light a fire under LGND!
Sentiment: Strong Buy
Climacteric. 2014 Dec 16:1-18. [Epub ahead of print]
Cardiovascular safety of conjugated estrogens plus bazedoxifene: meta-analysis of the SMART trials.
Komm BS, Thompson JR, Mirkin S.
Abstract Objectives: Five randomized, phase 3 trials demonstrated the efficacy and safety of conjugated estrogens/bazedoxifene (CE/BZA) in treating menopausal symptoms and preserving bone. This pooled analysis of these studies describes cardiovascular safety of CE/BZA. Methods: We pooled cardiovascular adjudicated safety data from healthy, nonhysterectomized, postmenopausal women who received ≥1 dose of CE 0.45 mg/BZA 20 mg (n=1585), CE 0.625 mg/BZA 20 mg (n=1583), any CE/BZA dose (n=4868), or placebo (n=1241) for up to 2 years in 5 trials. Venous thromboembolic events (VTEs), coronary heart disease (CHD), and cerebrovascular events were reviewed by 3 different independent adjudication committees and summarized using a meta-analytic approach. Results: Rate of VTEs per 1000 woman-years (95% confidence interval [CI]) was 0.3 (0.0-2.0) in women taking CE 0.45 mg/BZA 20 mg, 0 (0.0-1.5) in those taking CE 0.625 mg/BZA 20 mg, 0.7 (0.0-1.5) among women taking any CE/BZA dose, and 0.6 (0.0-2.9) with placebo. Incidence of stroke per 1000 woman-years (95% CI) was 0.4 (0.0-2.4), 0.2 (0.0-1.9), 0.44 (0.0-1.1), and 0.0 (0.0-1.7), respectively. CHD rate per 1000 woman-years was 2.6 (0.0-5.6), 1.4 (0.0-3.9), and 2.0 (0.0-5.2). Compared with placebo, relative risk (95% CI) with any CE/BZA dose was 0.5 (0.1-1.8) for VTE, 0.5 (0.1-2.6) for stroke, and 0.63 (0.23-1.74) for CHD. Conclusions: Up to 2 years of CE 0.45 or 0.625 mg with BZA 20 mg had an acceptable cardiovascular safety profile, with rates of stroke and CHD comparable to placebo in healthy postmenopausal women. VTE risk was low.
Sentiment: Strong Buy
AS LGND is one of the few Biotechs (of quality) that are down YTD. I assume some pressure is due to tax loss season. LGND is again underperforming the IBB. Which should not be the case, if other sectors are any lesson, Royalties tend to outperform.
However: I assume this presents a interesting opportunity going into the new year. Q1 2015 LGND might then strongly outperform.
MR. HIggins: Please , Please . Please put to use that money do anything ,give it awawy ,if you must , but use it.Money get stale when it is not used .Please . Thank you.
J Pharmacol Exp Ther. 2014 Dec 15. pii: jpet.114.221747. [Epub ahead of print]
and cardiac transplantation: there is substantial market opportunity here.
THROMBOPOIETIN RECEPTOR AGONISTS PROTECT HUMAN CARDIAC MYOCYTES FROM INJURY BY ACTIVATION OF CELL SURVIVAL PATHWAYS.
Baker JE1, Su J2, Koprowski S2, Dhanasekaran A3, Aufderheide TP2, Gross GJ2.
Thrombopoietin confers immediate protection against injury caused by ischemia/reperfusion in the rat heart. Eltrombopag is a small molecule agonist of the thrombopoietin receptor; the physiological target of thrombopoietin. However, the ability of eltrombopag and thrombopoietin to protect human cardiac myocytes against injury and the mechanisms underlying myocyte protection are not known. Human cardiac myocytes (n= 6-10/group) were treated with eltrombopag (0.1- 30.0 µM) or thrombopoietin ( 0.1 - 30.0 ng/ml) and then subjected to 5 hours of hypoxia (95% N2/5%CO2) and 16 hours of reoxygenation to determine their ability to confer resistance to myocardial injury. The thrombopoietin receptor (c-Mpl) was detected in unstimulated human cardiac myocytes by western blotting. Eltrombopag and thrombopoietin confer immediate protection to human cardiac myocytes against injury from hypoxia/reoxygenation by decreasing necrotic and apoptotic cell death in a concentration-dependent manner with an optimal concentration of 3 µM for eltrombopag and 1.0 ng/ml for thrombopoietin. The extent of protection conferred with eltrombopag is equivalent to that of thrombopoietin. Eltrombopag and thrombopoietin activate multiple pro-survival pathways; inhibition of JAK-2, src kinase, Akt/PI3 kinase, p44/42 MAPK and p38 MAPK abolished cardiac myocyte protection by eltrombopag and thrombopoietin. Eltrombopag and thrombopoietin may represent important and potent agents for immediately and substantially increasing protection of human cardiac myocytes, and may offer long-lasting benefit through activation of pro-survival pathways during ischemia.
Sentiment: Strong Buy
Buy SPPI Five drugs on the market big pipeline with two potential blockbuster, cash on the balance sheet , a mature CEO ,and many shareholder tha twill be happy to sell their shares .Let's put our money to use.
The stock is at 52 week lows if you are implementing a buy back now would be a GREAT time!!! Holy cow!! Build some shareholder value what are you waiting for. WE don't need a buyback to drive the stock we need visibility, product news, increase earnings and a marketing plan to attract new investors. This is the best story out there!! Come on
HEALTH CANADA APPROVES MERCK’S POSANOL® (POSACONAZOLE) SOLUTION FOR INJECTION, A NEW INTRAVENOUS FORMULATION
Kirkland, Quebec – November 13, 2014 – Merck, known as MSD outside of Canada and the United States, today announced that Health Canada has approved POSANOL® (posaconazole) Solution for Injection 300 mg/vial, a new intravenous (IV) formulation. POSANOL is also approved in Canada in two formulations for oral administration: POSANOL Delayed-Release Tablets 100 mg, and POSANOL Oral Suspension 40 mg/mL. POSANOL Solution for Injection is expected to be available as early as the end of November, 2014.
Invasive fungal infections are a major cause of morbidity and mortality, in particular among patients who are severely immunocompromised such as patients receiving chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) and hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (GVHD). Mortality rates from aspergillosis have been reported to be at least 50% in patients with neutropenia and 86% in patients who have undergone hematopoietic stem cell transplant.1
"With the approval of posaconazole for intravenous use, we now have a choice of three formulations to help meet different patient needs,” said Dr. Michel Laverdière, Infectious Disease Specialist at Maisonneuve Rosemont Hospital. "This new IV formulation will facilitate the management of patients unable to take medications orally, for example patients affected by vomiting, mucositis, or diarrhea.”
Sentiment: Strong Buy
Int J Infect Dis. 2014 Oct 30. pii: S1201-9712(14)01655-5. doi: 10.1016/j.ijid.2014.10.009. [Epub ahead of print]
(Licensed to LGND partner Rib-x/Melinta Therapeutics):
A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections.
O'Riordan W1, Mehra P2, Manos P3, Kingsley J4, Lawrence L5, Cammarata S5.
A randomized, double-blind, multicenter trial compared 2 doses of delafloxacin with tigecycline in patients with various complicated skin and skin-structure infections (wound infections following surgery, trauma, burns, or animal/insect bites; abscesses; or cellulitis).
Patients were randomized 1:1:1 to receive delafloxacin 300mg IV every 12hours, delafloxacin 450mg IV every 12hours, or tigecycline 100mg IV x 1, followed by 50mg IV every 12hours; randomization was stratified by infection type. Duration of therapy was 5-14 days. The primary efficacy analysis, performed on the clinically evaluable (CE) population at the test-of-cure (TOC) visit (14-21 days after final dose of study drug), compared clinical response rates in the delafloxacin and tigecycline arms. Clinical response rates in the 2 delafloxacin arms were also compared.
Among CE patients, clinical cure rates at TOC visit were similar in the delafloxacin and tigecycline arms (94.3%, 92.5%, and 91.2%, respectively in delafloxacin-300-mg, delafloxacin-450-mg, and tigecycline arms). Overall, the most frequent adverse events were nausea, vomiting, and diarrhea; the 300-mg delafloxacin arm was the best-tolerated regimen.
Delafloxacin is similarly effective as tigecycline for a variety of complicated skin and skin-structure infections, and was well tolerated.
Sentiment: Strong Buy
Its X-mas put some money to work!! We need news product updates and partner updates!! We have over 100 products hitting over 80 million in sales maybe we should hire a marketing firm. YTD the stock is FLAT!!! Shareholders are getting a bit impatient!! Time to expect better returns from a highly profitable company!!
The march up to the 70 -90 range needs to start at some point!! 4th quarter is around 25 million !! Then we are in 2015 setting up for 83 million with flat expenses!! I know of very few companies that can increase revenue and have the same expenses. That's a rare combination and will soon have a premium set on it!! over a 2 billion market cap is expected!! 2016 is over 107 million.
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple MyelomaLenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma.
We randomly assigned 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group). The primary end point was progression-free survival.RESULTS
Progression-free survival was significantly improved with carfilzomib (median, 26.3 months, vs. 17.6 months in the control group; hazard ratio for progression or death, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P=0.0001). The median overall survival was not reached in either group at the interim analysis. The Kaplan–Meier 24-month overall survival rates were 73.3% and 65.0% in the carfilzomib and control groups, respectively (hazard ratio for death, 0.79; 95% CI, 0.63 to 0.99; P=0.04). The rates of overall response (partial response or better) were 87.1% and 66.7% in the carfilzomib and control groups, respectively (P
Sentiment: Strong Buy
One of the bears (Lemelsons) other arguements were scepticism about Kyprolis - here is some snippet from Adam F. / The Street on Kyprolis - all sounds very good:
"4. Amgen (AMGN) had a very good weekend in San Francisco. Doctors I spoke with and heard from were effusive in their praise for the multiple myeloma drug Kyprolis based on results from the ASPIRE study. And FDA did Amgen a big favor by approving the novel immunotherapy Blincyto right before we all arrived here.
near term lowering of earnings have caused a drop in price.
Stock has been fully priced for a while.
However the fact that Higgins hasn't done major repurchases with the funds means that he is looking to acquire a small company to add to the pipeline.
That and combine that with some expected catalysts in 2015 should eventually move the needle on LGND
The BACE program would be the big mover
Osteoporos Int. 2014 Dec 2. [Epub ahead of print]
Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan.
Ohta H1, Solanki J.
The incidence of osteoporosis-related fractures in Asian countries is steadily increasing. Optimizing osteoporosis treatment is especially important in Japan, where the rate of aging is increasing rapidlyelderly population is increasing rapidly and life expectancy is among the longest in the world. There are several therapies currently available in Japan for the treatment of postmenopausal osteoporosis, each with a unique risk/benefit profile. A novel selective estrogen receptor modulator, bazedoxifene (BZA), was recently approved for the treatment of postmenopausal osteoporosis in Japan. Results from a 2-year, phase 2 trial in postmenopausal Japanese women showed that BZA significantly improved lumbar spine and total hip bone mineral density compared with placebo, while maintaining endometrial and breast safety, consistent with results from 2 global, phase 3 trials including a 2-year osteoporosis prevention study and a 3-year osteoporosis treatment study. In the pivotal 3-year treatment study, BZA significantly reduced the incidence of new vertebral fractures compared with placebo; in a post hoc analysis of a subgroup of women at higher risk of fractures, BZA significantly reduced the risk of nonvertebral fractures compared with placebo and raloxifene. A 2-year extension of the 3-year treatment study demonstrated the sustained efficacy of BZA over 5 years of treatment. BZA was generally safe and well tolerated in these studies. In a "super-aging" society such as Japan, long-term treatment for postmenopausal osteoporosis is a considerable need. BZA may be considered as a first choice for younger women anticipating long-term treatment, and also an appropriate option for older women who are unable or unwilling to take bisphosphonates.
Sentiment: Strong Buy